Table 1 The studies’ characteristics of all included articles.

From: Impact of family history on oncological outcomes in primary therapy for localized prostate cancer patients: a systematic review and meta-analysis

First author of study and [Ref.]

Country

Recruitment period

Study design

Level of evidence

Definition of FH

Total

FH

NOS

Yes

No

Hanus et al. [24]

US

1987–1996

Cohort, retrospective

2B

One or more first-degree relatives

1164

148

1016

6

Ray et al. [25]

US

1983–2001

Cohort, retrospective

2B

One or more first-degree relatives

536

97

439

7

Lee et al. [26]

US

1989–2000

Cohort, retrospective

2B

One or more first-degree relatives

556

103

453

7

Spangler et al. [27]

US

1995–2002

Cohort, retrospective

2B

One or more first-degree relatives

506

179

327

6

Roehl et al. [28]

US

1983–2003

Cohort, retrospective

2B

One or more first-degree relatives

1186

Sibiling pairs (n = 141)

Hereditary (n = 114)

High density family member (n = 37)

968

7

Kupelian et al. [29]

US

1986–2002

Cohort, retrospective

2B

One or more first-degree relatives

4112

659

3453

7

Peters et al. [30]

US

1992–2005

Cohort, retrospective

2B

One or more first-degree relatives

1737

187

1550

7

Bagshaw et al. [31]

US

1989–2007

Cohort, retrospective

2B

One or more first-degree relatives

1711

386

1325

7

Westerman et al. [13]

US

1987–2010

Cohort, retrospective

2B

One or more first-degree relatives

16,472

5323

11,149

7

Thalgott et al. [32]

Germany

1994–2010

Cohort, retrospective

2B

HPC: subgroup of familial PCa with a likelihood of genetic predisposioton

SPC: two or more brothers aged at least 60 y and negative anamnesces for PCa

11,130 (FPC + SPC n = 2775)

HPC (n = 807)

FPC (n = 2251)

Non-FPC (n = 8072)

SPC (n = 524)

7

Lee et al. [6]

Korea

2006–2015

Cohort, retrospective

2B

One or more first-degree relatives

606

39

567

6

  1. FH family history, PCa prostate cancer, HPC hereditary prostate cancer, FPC familial prostate cancer, SPC sporadic prostate cancer, NOS Newcastle-Ottawa Scale.